The Sunday Times said a “well-placed source” confirmed the talks but added the “complexity of the deal made a decision some way off.” Elan, a co-marketer with Biogen Idec of multiple sclerosis drug Tysabri, hired Citigroup in January to conduct a review of the business and said at the time a merger or sale of the company was possible.
It said on June 10 that it expected to conclude a strategic transaction “in the near term,” after talking over the past few months with a number of the global players in pharmaceuticals and biotechnology.
Analysts say Elan is running out of options for a strategic partnership as earlier market talk of a link-up with companies such as Pfizer or Lundbeck have failed.
Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks